Claims
- 1. The method of preventing rapid degradation of 9-.beta.-D-arabinofuranosyladenine or a pharmaceutically acceptable salt thereof in a mammal undergoing systemic treatment with 9-.beta.-D-arabinofuranosyladenine or a pharmaceutically acceptable salt thereof by inhibiting the conversion of 9-.beta.-D-arabinofuranosyladine or a pharmaceutically acceptable salt thereof comprising administering to said mammal an effective degradation inhibition amount of erythro-9-(2-hydroxy-3-nonyl)adenine or a pharmaceutically acceptable salt thereof.
- 2. The method of claim 1 in which the mammal is administered the 9-.beta.-D-arabinofuranosyladenine or a pharmaceutically acceptable salt thereof by oral or parenteral administration and said erythro-9-(2-hydroxy-3-nonyl)adenine or a pharmaceutically acceptable salt thereof is administered orally or parenterally.
- 3. The method of claim 2 in which said erythro-9-(2-hydroxy-3-nonyl)adenine or a pharmaceutically acceptable salt is administered in a tablet, in a capsule or in an injectable solution.
- 4. The method of claim 2 in which 9-.beta.-D-arabinofuranosyladenine is being administered to the mammal.
- 5. The method of claim 2 in which the hydrochloride salt of erythro-9-(2-hydroxy-3-nonyl)adenine is administered.
- 6. The method of claim 4 in which the hydrochloride salt of erythro-9-(2-hydroxy-3-nonyl)adenine is administered.
Priority Claims (1)
Number |
Date |
Country |
Kind |
6173/75 |
Feb 1975 |
GBX |
|
Parent Case Info
This is a continuation of application Ser. No. 838,167 filed Sept. 30, 1977 now abandoned which is in turn a continuation of Ser. No. 605,718 filed Aug. 18, 1975, now abandoned.
Non-Patent Literature Citations (2)
Entry |
Koshiura et al., Cancer Research, vol. 28, 1968, pp. 1014-1020. |
Schaeffer et al., J. Med. Chem., vol. 17, No. 1, pp. 6-8 (1973). |
Continuations (2)
|
Number |
Date |
Country |
Parent |
838167 |
Sep 1977 |
|
Parent |
605718 |
Aug 1975 |
|